Medication info
Janudau Tablet 100 mg (Sitagliptin Hydrochloride Monohydrate)

Janudau Tablet 100 mg (Sitagliptin Hydrochloride Monohydrate)

Prescription medicationTabletOral
Ingredient · strength
Sitagliptin Hydrochloride Hydrate›113.4mg / 1 tablet
Manufacturer / importer
Daewoong Bio Co., Ltd.
Appearance
Light orange, round, biconvex film-coated tablet
Packaging
30 tablets/box (10 tablets/PTP X 3)
Approval status
Active

MFDS item code 202004027 · Approved 2020.05.29 · Insurance code 694003160

Summary

Main use
Improvement of glycemic control in type 2 diabetes mellitus
Who takes it
Adults
Adult dose
This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Ingredients

Manufacturer
Daewoong Bio Co., Ltd.

Efficacy & effects

Improvement of glycemic control in type 2 diabetes mellitus

  • Difficulty in blood sugar control for patients with type 2 diabetes
View approved original text

This medication is used to assist in blood sugar control in patients with type 2 diabetes in conjunction with diet and exercise. It can be administered alone, but in cases where there is no experience with diabetes drug treatment and blood sugar control is difficult with monotherapy, it may be combined with metformin. Additionally, if blood sugar control is insufficient with monotherapy of sulfonylureas, metformin, thiazolidinediones, or insulin, this medication is also used in combination to help improve blood sugar levels. Therefore, this medication is utilized for effective blood sugar control in patients with type 2 diabetes.

How to take

Adult dose

This medicine is administered at 100 mg once daily, either as monotherapy or in combination therapy; the maximum daily dose is 100 mg. This medicine may be taken without regard to meals. When this medicine is coadministered with a sulfonylurea or insulin, a reduction in the dose of the sulfonylurea or insulin may be considered to reduce the risk of hypoglycemia caused by the sulfonylurea or insulin (see Precautions for Use, 5. General Precautions). Patients with renal impairment Because dose adjustment according to renal function is necessary, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. 1. No dose adjustment is necessary in patients with mild renal impairment (glomerular filtration rate [eGFR] ≥ 60 mL/min/1.73 m2 and < 90 mL/min/1.73 m2). 2. No dose adjustment is necessary in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 45 mL/min/1.73 m2 and < 60 mL/min/1.73 m2). 3. Administer 50 mg once daily in patients with moderate renal impairment (glomerular filtration rate [eGFR] ≥ 30 mL/min/1.73 m2 and < 45 mL/min/1.73 m2). 4. Administer 25 mg once daily in patients with severe renal impairment (glomerular filtration rate [eGFR] ≥ 15 mL/min/1.73 m2 and < 30 mL/min/1.73 m2) or end-stage renal disease (ESRD) requiring hemodialysis or peritoneal dialysis (glomerular filtration rate [eGFR] < 15 mL/min/1.73 m2). This medicine may be administered without regard to the timing of dialysis.

Precautions

This medication may cause allergic reactions, so if symptoms such as skin rash, hives, or difficulty breathing occur during use, it should be discontinued immediately and consult a physician. Moreover, acute pancreatitis, a serious pancreatic inflammation, may occur, so it is important to carefully observe for abdominal pain, vomiting, or severe nausea and to discontinue use if symptoms are suspected. It should not be administered to patients with type 1 diabetes or diabetic ketoacidosis, and use should be avoided if there is hypersensitivity to this medication or its components. For patients with impaired kidney function, the dosage must be adjusted as the drug may not be adequately excreted from the body, especially in patients with end-stage renal disease undergoing dialysis, where low-dose usage is recommended. When used in combination with other hypoglycemic agents, there may be an increased risk of hypoglycemia, so caution should be exercised for hypoglycemic symptoms when taking insulin or sulfonylureas, and adjustments to the dosages of other medications may be necessary. Severe arthralgia or blistering skin diseases may occur, and if such symptoms arise, inform a physician immediately and consider discontinuing the medication. Use of this medication is not recommended during pregnancy or breastfeeding, and safety and efficacy have not been established for children and adolescents under 18 years of age. Elderly individuals may have impaired kidney function, so it is advisable to evaluate kidney function before administration and to periodically check kidney status after administration. In case of overdose, general symptomatic treatment should be initiated, and blood dialysis may be considered to remove some of the drug if necessary. This medication has no issues with cardiovascular safety; however, some adverse reactions such as upper respiratory infections, headaches, rhinitis, diarrhea, and nausea have been reported, so caution is advised if symptoms occur. Finally, there are no significant interactions with other medications, but there may be a slight increase in blood levels when taken with digoxin, so monitoring is necessary.

Side effects

Severe hypersensitivity reactions, anaphylaxis, angioedema, Stevens-Johnson syndrome, acute pancreatitis, hypoglycemia, upper respiratory infection, nasopharyngitis, headache, diarrhea, abdominal pain, nausea, constipation, vomiting, joint pain accompanied by severe symptoms and disabilities, bullous pemphigoid, myalgia, limb pain, back pain, interstitial lung disease, pruritus, thrombocytopenia, rhabdomyolysis, elevated liver enzymes, acute kidney failure, pneumonia, diabetes complications, metabolic acidosis, falls, cardiac arrest, dyspepsia, dizziness, increased blood triglycerides, gastritis, weight loss, hypertension, hypernatremia, erectile dysfunction

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to prevent air from entering, and it is recommended to store it at room temperature between 1 to 30 degrees Celsius. This will help maintain the effectiveness of the medication.

Appearance and packaging

Appearance

Light orange, round, biconvex film-coated tablet

Package unit

30 tablets/box (10 tablets/PTP X 3)

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.